FDA Plans Independent Audit of Drug Application Transparency Initiative

As part of fulfilling a key user fee commitment, the FDA is asking the White House to approve plans to survey companies that submit applications to the agency to assess the effectiveness of a new drug approvals transparency initiative.
Clinical Trials Advisor